Brief: Alphamab Oncology Posts HY Loss For Period RMB147.3 Million
Aug 31 (Reuters) - Alphamab Oncology 9966.HK :
* HY LOSS FOR PERIOD RMB147.3 MILLION VERSUS LOSS RMB267.4
MILLION
* HY REVENUE RMB53.6 MILLION
Source text for Eikon: ID:nHKS4v93fv
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)